↓ Cooling Business 🔮 fades FDA staff flags data concerns about Capricor's therapy; shares plunge Capricor Therapeutics faces market volatility and legal investigations following the release of FDA staff documents regarding its therapy, Deramiocel. 4 sources 5 articles v 3 11h ago
↑ Rising Business 🔮 fades Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug FDA staff have raised significant concerns regarding the efficacy data for Capricor Therapeutics' experimental heart disease therapy for Duchenne patients. 10 sources 11 articles v 9 8h ago